DaVita stock gains 1.08 percent as Q2 EPS beats consensus

DaVita stock was trading at USD 185.71 on the NYSE on September 23, 2026, up 1.08 percent from the previous close of USD 183.72. The move comes as the kidney-care provider combines fresh second-quarter growth with earnings above consensus.

Second-quarter earnings beat estimates

DaVita generated USD 3.554 billion in revenue in Q2 2026, up 5.2 percent from the year-earlier period, while operating income reached USD 579 million. Diluted EPS was USD 4.02, compared with consensus of USD 3.88, a beat of USD 0.14, according to Quartr and MarketBeat.

The quarterly operating margin was 16 percent, compared with 14 percent in Q1 2026, while net income increased to USD 343.223 million from USD 275.035 million. The sequential improvement gives the stock a more specific earnings anchor than the daily move alone.

Guidance sets the valuation test

DaVita maintained fiscal 2026 EPS guidance of USD 14.10 to USD 15.20, while the latest quarter delivered USD 4.02 in diluted EPS. That range places execution and the next quarterly update at the center of the investment case, rather than the single-session change.

Revenue growth and the earnings beat point in the same direction, but the share price remains USD 61.78 below its 52-week high of USD 247.49. The gap is 24.96 percent, leaving the current quotation materially below the yearly peak despite the Q2 comparison.

DaVita stock stays below its high

On September 23, 2026, DaVita stock stood at USD 185.71 on the NYSE, with a market capitalization of USD 11.923 billion and a 52-week range of USD 101.00 to USD 247.49. The intraday gain was 1.08 percent.